Steven H Itzkowitz, MD
- PROFESSOR | Medicine, Gastroenterology
- PROFESSOR | Oncological Sciences
Research Topics:Aerodigestive Tract, Cancer, Epithelial Cells, Inflammatory Bowel Disease (IBD)
Steven H. Itzkowitz, M.D. is Professor of Medicine and Oncological Sciences, and Director of the GI Fellowship Program at the Icahn School of Medicine at Mount Sinai. He is past Chair of the Gastrointestinal Oncology Section of the American Gastroenterological Association, past President of the New York Gastroenterological Association, and immediate past Co-Chair of the New York Citywide Colon Cancer Control Coalition (C5). He is a recipient of a distinguished Jacobi Medallion from the Mount Sinai School of Medicine and a Gold Humanism Award.
Dr. Itzkowitz has served as a Study Section member for the National Cancer Institute, Veteran's Affairs Merit Review Board, Crohn's and Colitis Foundation of America, and US-Israel Binational Science Foundation, and as an editor of the International Journal of Colorectal Disease, and Gut and Liver, and associate editor of Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, and Gastric Cancer. He spearheaded efforts to secure NCI funding for the East Harlem Partnership for Cancer Awareness: a program based at Mount Sinai, designed to raise awareness in the East Harlem community regarding the risks and treatment for several common cancers including colon cancer.
Dr. Itzkowitz's research interests are in the field of gastrointestinal cancer. His laboratory conducts research into the microbiome of patients with inflammatory bowel disease (IBD). Clinical studies have focused on detecting and preventing colon cancer in inflammatory bowel disease, reducing disparities in colon cancer screening, and developing new non-invasive stool DNA tests for colon cancer.
In the News: Dr. Steven Itzkowitz was recently featured in INSIDE MOUNT SINAI for his work in increasing screening colonoscopy rates in NYC with the C5 Coalition.
American Board of Internal Medicine
- Colon Polypectomy
- Colon Polyps
- Colorectal Cancer
- Crohn's Disease
- Familial Adenomatous Polyposis
- Flexible Sigmoidoscopy
- Inflammatory Bowel Disease
- Iron-Deficiency Anemia
- Juvenile Polyposis Syndrome
- Lynch Syndrome
- Peutz Jeghers Syndrome
- Polyposis Syndromes
- Rectal Cancer
- Ulcerative Colitis
- Upper GI Endoscopy
Multi-Disciplinary Training AreaCancer Biology [CAB]
MD, Mount Sinai School of Medicine
Residency, Internal Medicine, Bellevue/NYU Hospital Center
Residency, Internal Medicine, Bellevue/NYU Hospital Center
Fellowship, Gastroenterology, University of Cal. San Francisco
Patient Advocacy Award
Excellence in Teaching Award
Academic Achievement Award (Senior Faculty)
Reducing disparities in screening colonoscopy
Dr. Itzkowitz helped spearhead community outreach efforts to enhance awareness of colon cancer in East Harlem. He and his colleagues have demonstrated the effectiveness of new strategies to improve the completion rates of screening colonoscopy among minority individuals by employing patient navigators within an open access referral system. This model has now been accepted by most medical centers and ambulatory clinics.
Progression of Neoplasia in Inflammatory Bowel Disease
Studies at Mount Sinai are examining clinical and pathological risk factors to help better understand the factors that promote progression from inflammation to precancerous and cancerous lesions in the colon in patients with IBD. Dr. Itzkowitz is the PI on a new registry that will follow patients with IBD and a past history of cancer who are treated with immune modulating medicines for their IBD, in order to determine whether these medications are associated with the development of recurrent or new cancers.
Mechanisms of inflammation-associated carcinogenesis
Laboratory investigation is exploring the profile of intestinal microbiota in patients with inflammatory bowel disease (IBD) who have primary sclerosing cholangitis - conditions that predispose to colon cancer.
Cancer Risk in Patients with Inflammatory Bowel Disease
Many patients with inflammatory bowel disease (IBD) take medicines that affect their immune system. Most of these drugs were initially tested in patients with IBD who did not have a past history of cancer for fear that these agents might promote a recurrence or development of a new cancer. But a recent study by Dr. Itzkowitz and coworkers indicates that even in those patients with IBD who have a history of cancer, taking immune modulating medicines did not predispose them to a recurrence of their cancer or the development of a new cancer. Dr. Itzkowitz is now heading a multicenter registry to follow patients with IBD who have a history of cancer to track their rates of new or recurrent cancer in a prospective fashion.
Developing non-invasive colon cancer screening tests
Dr. Itzkowitz's team was part of a national study that demonstrated the utility of stool DNA testing for detecting colon cancer and precancerous polyps in the general population. He is now leading a national study that is testing a modified version of the stool DNA test in patients with IBD who are at increased risk for developing colorectal cancer.
Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, Itzkowitz S, Hu J. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Alimentary pharmacology & therapeutics 2016 Apr; 43(7).
Itzkowitz SH, Winawer SJ, Krauskopf M, Carlesimo M, Schnoll-Sussman FH, Huang K, Weber TK, Jandorf L. New York Citywide Colon Cancer Control Coalition: A public health effort to increase colon cancer screening and address health disparities. Cancer 2016 Jan; 122(2).
Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Jan; 14(1).
Ladabaum U, Mannalithara A, Jandorf L, Itzkowitz SH. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Cancer 2015 Apr; 121(7).
Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. The New England journal of medicine 2015 Apr; 372(15).
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. The New England journal of medicine 2014 Apr; 370(14).
Lee KK, Jandorf L, Thélèmaque L, Itzkowitz SH. Colorectal neoplasia detection among black and Latino individuals undergoing screening colonoscopy: a prospective cohort study. Gastrointestinal endoscopy 2014 Mar; 79(3).
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer cell 2013 May; 23(5).
Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013 Nov; 62(11).
Jandorf L, Stossel LM, Cooperman JL, Graff Zivin J, Ladabaum U, Hall D, Thélémaque LD, Redd W, Itzkowitz SH. Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities. Cancer 2013 Feb; 119(3).